{"id":48727,"date":"2022-09-23T01:01:50","date_gmt":"2022-09-22T23:01:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/appili-therapeutics-announces-results-of-annual-and-special-meeting-of-shareholders\/"},"modified":"2022-09-23T01:01:50","modified_gmt":"2022-09-22T23:01:50","slug":"appili-therapeutics-announces-results-of-annual-and-special-meeting-of-shareholders","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/appili-therapeutics-announces-results-of-annual-and-special-meeting-of-shareholders\/","title":{"rendered":"Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders"},"content":{"rendered":"
\n

HALIFAX, Nova Scotia–(BUSINESS WIRE)–Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the \u201cCompany\u201d or \u201cAppili\u201d), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.\n<\/p>\n

<\/a><\/p>\n

\nBased on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich, Theresa Matkovits, Rochelle Stenzler and Armand Balboni.\n<\/p>\n

\nVoting results for each director are summarized below:\n<\/p>\n\n\n\n\n\n\n\n\n
\n

\nName of Nominee<\/span><\/b>\n<\/p>\n<\/td>\n

\n

\nPercentage of Votes For<\/span><\/b>\n<\/p>\n<\/td>\n

\n

\nPercentage of Votes Against<\/span><\/b>\n<\/p>\n<\/td>\n

\n

\nPercentage of Votes Withheld<\/span><\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nIan Mortimer\n<\/p>\n<\/td>\n

\n

\n19,490,794 (98.42%)\n<\/p>\n<\/td>\n

\n

\n307,825 (1.55%)\n<\/p>\n<\/td>\n

\n

\n5,300 (0.03%)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nBrian Bloom\n<\/p>\n<\/td>\n

\n

\n16,812,009 (84.89%)\n<\/p>\n<\/td>\n

\n

\n2,985,610 (15.08%)\n<\/p>\n<\/td>\n

\n

\n6,300 (0.03%)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nJuergen Froehlich\n<\/p>\n<\/td>\n

\n

\n16,808,009 (84.87%)\n<\/p>\n<\/td>\n

\n

\n2,989,610 (15.10%)\n<\/p>\n<\/td>\n

\n

\n6,300 (0.03%)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTheresa Matkovits\n<\/p>\n<\/td>\n

\n

\n19,489,794 (98.41%)\n<\/p>\n<\/td>\n

\n

\n307,825 (1.55%)\n<\/p>\n<\/td>\n

\n

\n6,300 (0.03%)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRochelle Stenzler\n<\/p>\n<\/td>\n

\n

\n19,490,794 (98.42%)\n<\/p>\n<\/td>\n

\n

\n307,825 (1.55%)\n<\/p>\n<\/td>\n

\n

\n5,300 (0.03%)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nArmand Balboni\n<\/p>\n<\/td>\n

\n

\n16,808,009 (84.87%)\n<\/p>\n<\/td>\n

\n

\n2,989,610 (15.10%)\n<\/p>\n<\/td>\n

\n

\n6,300 (0.03%)\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nIn addition to the election of the directors of the Company as noted above, the Shareholders:\n<\/p>\n